Format

Send to

Choose Destination
Ital J Pediatr. 2017 Sep 6;43(1):78. doi: 10.1186/s13052-017-0393-5.

Long-term treatment with low-dose medicine in chronic childhood eczema: a double-blind two-stage randomized control trial.

Author information

1
Department of Pediatric Allergy, San Pietro Hospital Fatebenefratelli, Via Cassia, 600, Rome, Italy. carellorossella@gmail.com.
2
Clinical Research Unit, Guna S.p.a., Milan, Italy.
3
Department of Pharmacology and Therapeutic Research, Italian National Institute of Health, Rome, Italy.
4
Department of Pediatric Allergy, San Pietro Hospital Fatebenefratelli, Via Cassia, 600, Rome, Italy.

Abstract

BACKGROUND:

The efficacy of low-dose medicine (LDM) in childhood mild/moderate eczema is not known. We conducted a double-blind, two-stage, randomized, placebo-controlled clinical trial, lasting 23 months, to address this issue.

METHOD:

Eighty children with chronic mild/moderate eczema were randomly allocated to Group A (placebo) or Group B (treatment group; Galium-Heel®, a low-dose multicomponent medicine based upon natural substances; Guna-Interleukin 12 and Guna-Interferon-γ administered twice a day for six non-consecutive months for each stage). LDM is characterized by the use of biological molecules, such as cytokines, neuropeptides, growth factors, hormones at very low concentrations, which correspond to physiological levels within the human body. The dosage of the cytokines used in this trial (IFN-γ and IL-12) is 10 fg/ml. The SCORAD index was evaluated by the same operator: subjects with a SCORAD index below 20 were considered to have mild eczema (61/80; mean: 10.79), whereas a SCORAD index between 20-50 indicated moderate eczema (19/80; mean: 26.84). The data of 66/80 children were analyzed in stage 1 and those of 62/66 children in stage 2. The primary outcome measure was reduction of eczema severity assessed by the SCORAD index. Secondary outcomes were disease-free interval, and treatment safety and tolerability.

RESULTS:

The decrease in disease severity was greater in Group B than in Group A already in stage 1 (a decrease 63.9% versus 53.2%), but the difference was not significant (p = 0.16). Moreover, subjective symptoms (itching and sleep disturbances) initially decreased and then worsened in Group A, whereas itching decreased linearly and sleep disturbances decreased significantly (p=0.049) in Group B.

CONCLUSIONS:

Preliminary evidence suggests potential benefit, but further work is needed to validate this approach.

TRIAL REGISTRATION:

The trial was registered with EudraCT number 2010-018640-13 through the database of the National Clinical Trials Monitoring Centre Database (Osservatorio delle Sperimentazioni Cliniche, OsSC) of the Italian Medicines Agency.

KEYWORDS:

Eczema; Immunomodulation; Low-dose medicine; SCORAD index

PMID:
28874171
PMCID:
PMC5585968
DOI:
10.1186/s13052-017-0393-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center